# Same Day Dosing of Pegfilgrastim in Breast Cancer Patients Undergoing Chemotherapy (TAC)

> **NCT00115414** · PHASE2 · COMPLETED · sponsor: **Amgen**

## Conditions studied

- Breast Cancer
- Fever
- Neutropenia

## Interventions

- **DRUG:** pegfilgrastim
- **DRUG:** docetaxel
- **DRUG:** doxorubicin
- **DRUG:** cyclophosphamide

## Key facts

- **NCT ID:** NCT00115414
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2008-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00115414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00115414, "Same Day Dosing of Pegfilgrastim in Breast Cancer Patients Undergoing Chemotherapy (TAC)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00115414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*